Alternative Protein Scaffolds for Molecular Imaging and Therapy
暂无分享,去创建一个
[1] J. Willmann,et al. Pharmacokinetically Stabilized Cystine Knot Peptides That Bind Alpha-v-Beta-6 Integrin with Single-Digit Nanomolar Affinities for Detection of Pancreatic Cancer , 2011, Clinical Cancer Research.
[2] S. Gambhir,et al. A 2-Helix Small Protein Labeled with 68Ga for PET Imaging of HER2 Expression , 2009, Journal of Nuclear Medicine.
[3] Andreas Plückthun,et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. , 2007, Journal of molecular biology.
[4] C. Ballantyne,et al. Pharmacological strategies for lowering LDL cholesterol: statins and beyond , 2011, Nature Reviews Cardiology.
[5] A. Koide,et al. Stabilization of a fibronectin type III domain by the removal of unfavorable electrostatic interactions on the protein surface. , 2001, Biochemistry.
[6] G. Paesen,et al. Complement Inhibitor of C5 Activation from the Soft Tick Ornithodoros moubata , 2005, The Journal of Immunology.
[7] A. Plückthun,et al. DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[8] M. Mrugala,et al. Outside the Box—Novel Therapeutic Strategies for Glioblastoma , 2012, Cancer journal.
[9] S. Gambhir,et al. An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. , 2009, Bioconjugate chemistry.
[10] M. Gonda,et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. Koide,et al. Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain. , 2002, Protein engineering.
[12] Martin C. Wright,et al. Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2 , 2010, mAbs.
[13] K. Wittrup,et al. The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold. , 2010, Protein engineering, design & selection : PEDS.
[14] R. Kimura,et al. Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low‐nanomolar affinity , 2009, Proteins.
[15] A. Skerra,et al. High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2. , 2009, Journal of the American Chemical Society.
[16] Fredrik Y Frejd,et al. Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. , 2011, Protein engineering, design & selection : PEDS.
[17] Michael M. Schmidt,et al. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.
[18] Jennifer L. Lahti,et al. Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities. , 2009, Journal of molecular biology.
[19] Michaela Gebauer,et al. Engineered protein scaffolds as next-generation antibody therapeutics. , 2009, Current opinion in chemical biology.
[20] Adam P. Silverman,et al. Evaluation of a 64Cu-Labeled Cystine-Knot Peptide Based on Agouti-Related Protein for PET of Tumors Expressing αvβ3 Integrin , 2010, Journal of Nuclear Medicine.
[21] R. Kimura,et al. Functional Mutation of Multiple Solvent-Exposed Loops in the Ecballium elaterium Trypsin Inhibitor-II Cystine Knot Miniprotein , 2011, PloS one.
[22] A. Plückthun,et al. A Novel Fusion Toxin Derived from an EpCAM-Specific Designed Ankyrin Repeat Protein Has Potent Antitumor Activity , 2010, Clinical Cancer Research.
[23] S. Ståhl,et al. Non-immunoglobulin based protein scaffolds. , 2011, Current opinion in biotechnology.
[24] R. Kimura,et al. Preliminary evaluation of 177Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[25] E. Souied,et al. Phase I Mp0112 Wet AMD Study: Results Of A Single Escalating Dose Study With DARPin® MP0112 In Wet AMD , 2011 .
[26] S. Gambhir,et al. Engineered Two‐Helix Small Proteins for Molecular Recognition , 2009, Chembiochem : a European journal of chemical biology.
[27] H. Lundqvist,et al. Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. , 2007, Oncology reports.
[28] P. Nygren,et al. Alternative binding proteins: Affibody binding proteins developed from a small three‐helix bundle scaffold , 2008, The FEBS journal.
[29] Andreas Plückthun,et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. , 2010, Cancer research.
[30] V. Prasad,et al. Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules , 2010, Journal of Nuclear Medicine.
[31] J. Peterson,et al. Adnectin CT-322 inhibits tumor growth and affects microvascular architecture and function in Colo205 tumor xenografts. , 2010, International journal of oncology.
[32] V. Tolmachev,et al. Radionuclide molecular imaging using Affibody molecules. , 2010, Current pharmaceutical biotechnology.
[33] Christin Müller,et al. Intravenous application of an anticalin dramatically lowers plasma digoxin levels and reduces its toxic effects in rats. , 2012, Toxicology and applied pharmacology.
[34] H. Moch,et al. Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer , 2010, Modern Pathology.
[35] A. Lehmann. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery , 2008 .
[36] Christopher M Pirie,et al. Convergent Potency of Internalized Gelonin Immunotoxins across Varied Cell Lines, Antigens, and Targeting Moieties* , 2010, The Journal of Biological Chemistry.
[37] A. Wentzel,et al. The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery , 2006, Journal of drug targeting.
[38] Donghoon Lee,et al. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. , 2008, Small.
[39] Jakob Dogan,et al. Biophysical characterization of ZSPA‐1—A phage‐display selected binder to protein A , 2004, Protein science : a publication of the Protein Society.
[40] M. Hassan,et al. HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors , 2011, Clinical Cancer Research.
[41] Justin K Scheer,et al. CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy , 2012, Journal of Neuro-Oncology.
[42] S. Gambhir,et al. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. , 2009, Cancer research.
[43] Fredrik Y Frejd,et al. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications , 2010, FEBS letters.
[44] A. D. Rodrigues,et al. Development of a Carbon-14 Labeling Approach to Support Disposition Studies with a Pegylated Biologic , 2012, Drug Metabolism and Disposition.
[45] T. Wurch,et al. Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. , 2012, Trends in biotechnology.
[46] J. Wolchok,et al. Antibody therapy of cancer , 2012, Nature Reviews Cancer.
[47] Zhen Cheng,et al. Protein scaffold-based molecular probes for cancer molecular imaging , 2011, Amino Acids.
[48] Jean-Christophe Gelly,et al. KNOTTIN: the knottin or inhibitor cystine knot scaffold in 2007 , 2007, Nucleic Acids Res..
[49] S. Gambhir,et al. Cancer esearch rated Systems and Technologies Imaging of Tumor Neovascularization in a Transgenic R se Model with a Novel 64 Cu-DOTA-Knottin Peptide , 2010 .
[50] S. Gambhir,et al. Designed hydrophilic and charge mutations of the fibronectin domain: towards tailored protein biodistribution. , 2012, Protein engineering, design & selection : PEDS.
[51] Zhen Cheng,et al. Affibody modified and radiolabeled gold-iron oxide hetero-nanostructures for tumor PET, optical and MR imaging. , 2013, Biomaterials.
[52] J. Mazières,et al. A randomized, double-blinded, phase II study of paclitaxel/carboplatin (PC) plus CT-322 versus PC plus bevacizumab (Bev) as first-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). , 2012 .
[53] Gongping Yang,et al. Finger Vein Recognition Based on (2D)2 PCA and Metric Learning , 2012, Journal of biomedicine & biotechnology.
[54] S. Ståhl,et al. Affinity proteins and their generation , 2013 .
[55] Moritz A. Konerding,et al. Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing’s sarcoma A673-xenograft growth and normalize tumor vascular architecture , 2012, Angiogenesis.
[56] K. Wittrup,et al. Stability and CDR composition biases enrich binder functionality landscapes. , 2010, Journal of molecular biology.
[57] S. Gambhir,et al. A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[58] D. Neri,et al. Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications. , 2013, Bioconjugate chemistry.
[59] Sanjiv S. Gambhir,et al. Targeted Contrast-Enhanced Ultrasound Imaging of Tumor Angiogenesis with Contrast Microbubbles Conjugated to Integrin-Binding Knottin Peptides , 2010, Journal of Nuclear Medicine.
[60] Sanjiv S Gambhir,et al. 18F-Fluorobenzoate–Labeled Cystine Knot Peptides for PET Imaging of Integrin αvβ6 , 2013, The Journal of Nuclear Medicine.
[61] A. Plückthun,et al. Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.
[62] W. Stemmer,et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains , 2005, Nature biotechnology.
[63] J. Andersen,et al. Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain* , 2010, The Journal of Biological Chemistry.
[64] Arne Skerra,et al. Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins". , 2005, Drug discovery today.
[65] A. Plückthun,et al. DARPins: an efficient targeting domain for lentiviral vectors. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[66] B. Gong,et al. Novel complement inhibitor limits severity of experimentally myasthenia gravis , 2009, Annals of neurology.
[67] Martin C. Wright,et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor , 2011, mAbs.
[68] Nina M. Muñoz,et al. Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. , 2007, Cancer research.
[69] S. Ståhl,et al. Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber , 2009, Gene Therapy.
[70] J. Cochran,et al. Engineering knottins as novel binding agents. , 2012, Methods in enzymology.
[71] Y. Chen,et al. Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. , 2005, Protein engineering, design & selection : PEDS.
[72] Lin Sun,et al. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. , 2006, Chemistry & biology.
[73] M. Joppa,et al. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice , 2007, Peptides.
[74] Michelle L Colgrave,et al. Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. , 2004, Biochemistry.
[75] G. Steinberg,et al. SNX-111, a novel, presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits , 1997, Journal of the Neurological Sciences.
[76] A. Mamelak,et al. Imaging glioma extent with 131I-TM-601. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[77] S. Gambhir,et al. A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects. , 2010, Bioconjugate chemistry.
[78] A. A. Knecht. EVALUATION OF A , 1972 .
[79] J. Cochran,et al. Knottins: disulfide-bonded therapeutic and diagnostic peptides. , 2012, Drug discovery today. Technologies.
[80] P. Campochiaro,et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. , 2013, American journal of ophthalmology.
[81] Manuel Simon,et al. Designed ankyrin repeat proteins (DARPins) from research to therapy. , 2012, Methods in enzymology.
[82] Laura A. Sullivan,et al. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer , 2008, BMC Cancer.
[83] P. Kaye,et al. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies , 2009, Proceedings of the National Academy of Sciences.
[84] H. Willison,et al. C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome , 2008, Journal of the peripheral nervous system : JPNS.
[85] Joachim Feldwisch,et al. Design of an optimized scaffold for affibody molecules. , 2010, Journal of molecular biology.
[86] Laurent Chiche,et al. New binding specificities derived from Min-23, a small cystine-stabilized peptidic scaffold. , 2005, Biochemistry.
[87] Fredrik Y Frejd,et al. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor β in vivo. , 2011, Journal of molecular biology.
[88] Adam P. Silverman,et al. 111In-Labeled Cystine-Knot Peptides Based on the Agouti-Related Protein for Targeting Tumor Angiogenesis , 2012, Journal of biomedicine & biotechnology.
[89] E. Lundberg,et al. Selection and characterization of Affibody® ligands to the transcription factor c‐Jun , 2009, Biotechnology and applied biochemistry.
[90] K.,et al. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. , 2012, Journal of molecular biology.
[91] A. Tolcher,et al. Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin , 2011, Clinical Cancer Research.
[92] Sanjiv S Gambhir,et al. Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging. , 2012, Radiology.
[93] A. Kapila,et al. Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. , 2008, Journal of molecular biology.
[94] Michaela Gebauer,et al. Anticalins small engineered binding proteins based on the lipocalin scaffold. , 2012, Methods in enzymology.
[95] A novel radiofluorinated agouti-related protein for tumor angiogenesis imaging , 2013, Amino Acids.
[96] B. Ryffel,et al. Arthropod-Derived Histamine-Binding Protein Prevents Murine Allergic Asthma , 2004, The Journal of Immunology.
[97] M. Ballmaier,et al. Grafting of thrombopoietin‐mimetic peptides into cystine knot miniproteins yields high‐affinity thrombopoietin antagonists and agonists , 2006, The FEBS journal.
[98] R K Jain,et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.